CD200Fc

**CD200Fc** is a recombinant fusion protein consisting of the extracellular domain of CD200 (also known as OX-2), a type I transmembrane immunoregulatory glycoprotein from the immunoglobulin superfamily, fused to an IgG Fc region (murine IgG2a Fc modified to eliminate Fc receptor and complement binding). It acts as a potent agonist of the CD200 receptor (CD200R1), suppressing pro-inflammatory responses by promoting regulatory immune phenotypes, reducing cytokine production (e.g., IL-1β, IL-6, IL-10 in tumor contexts), inhibiting NLRP3 inflammasome and TLR4-NF-κB pathways, and enhancing anti-tumor immunity via increased IFN-γ, CD4+ and CD8+ T cells while decreasing myeloid suppressor cells. Developed or provided by entities including Genentech and R&D Systems/Bio-Techne (mouse and human versions available as research reagents), it has shown preclinical efficacy in models of intracerebral hemorrhage (ICH) by protecting blood-brain barrier integrity, aggressive breast cancer metastasis, LPS-induced cervical cancer inflammation, systemic lupus erythematosus (SLE) via dendritic cell modulation, and atopic dermatitis (related CD200-Fc analogs).[1][2][3][5][6][7][9]

Other names

CD200-FcCD-200-FcCD 200-Fc